Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Gains from Investment Securities (2023 - 2025)

Historic Gains from Investment Securities for Mereo BioPharma (MREO) over the last 3 years, with Q3 2025 value amounting to -$196000.0.

  • Mereo BioPharma's Gains from Investment Securities fell 43220.34% to -$196000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.8 million, marking a year-over-year decrease of 78380.06%. This contributed to the annual value of -$1.8 million for FY2024, which is 3089.01% down from last year.
  • Mereo BioPharma's Gains from Investment Securities amounted to -$196000.0 in Q3 2025, which was down 43220.34% from $101000.0 recorded in Q2 2025.
  • Mereo BioPharma's Gains from Investment Securities' 5-year high stood at $448000.0 during Q1 2024, with a 5-year trough of -$2.3 million in Q4 2024.
  • Moreover, its 3-year median value for Gains from Investment Securities was -$68500.0 (2024), whereas its average is -$359800.0.
  • As far as peak fluctuations go, Mereo BioPharma's Gains from Investment Securities skyrocketed by 18265.68% in 2024, and later tumbled by 43220.34% in 2025.
  • Quarter analysis of 3 years shows Mereo BioPharma's Gains from Investment Securities stood at -$897000.0 in 2023, then crashed by 159.31% to -$2.3 million in 2024, then surged by 91.57% to -$196000.0 in 2025.
  • Its Gains from Investment Securities was -$196000.0 in Q3 2025, compared to $101000.0 in Q2 2025 and -$416000.0 in Q1 2025.